This legal action highlights the regulatory gray zone surrounding kratom and synthetic mitragynine derivatives like 7-hydroxymitragynine, substances increasingly used by patients for pain and opioid withdrawal. Clinicians need to understand these products’ risks and their patients’ usage patterns, especially given their potential for dependence and drug interactions.
Missouri’s attorney general is pursuing legal action against American Shaman for selling kratom and 7-hydroxymitragynine (7-OH) products. Kratom contains mitragynine and 7-OH, compounds with opioid receptor activity that can provide analgesic and mood effects but also carry risks of dependence, withdrawal, and interactions with other medications. The synthetic 7-OH products may have enhanced potency compared to traditional kratom leaf preparations. These substances exist in a regulatory void, sold as supplements despite their pharmacologically active properties.
“I regularly encounter patients using kratom, often without mentioning it initially because they don’t consider it ‘medicine.’ The synthetic derivatives like 7-OH represent a concerning escalation in potency that patients may not fully understand when purchasing these products.”
💬 Join the Conversation
Have a question about how this applies to your situation? Ask Dr. Caplan →
Want to discuss this topic with other patients and caregivers? Join the forum discussion →
Have thoughts on this? Share it:
Table of Contents
FAQ
What is the clinical relevance rating of this cannabis news?
This article has been assigned CED Clinical Relevance #70, indicating “Notable Clinical Interest.” This means it contains emerging findings or policy developments that healthcare providers should monitor closely.
What medical areas does this cannabis research cover?
The research focuses on pain management and opioid-related treatments. It also addresses regulatory considerations and potential drug interactions involving cannabis therapeutics.
Why is this cannabis news considered clinically significant?
The content represents emerging findings or policy developments in cannabis medicine. Healthcare providers should pay attention to these developments as they may impact clinical practice and patient care decisions.
What should clinicians know about cannabis and opioid interactions?
This research addresses important drug interaction considerations between cannabis and opioids. Clinicians should be aware of potential therapeutic interactions and safety considerations when patients use both substances.
How does this relate to current pain management practices?
The findings provide insights into cannabis as a component of pain management strategies. This information may influence how healthcare providers approach multimodal pain treatment protocols and opioid alternatives.